• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AAIPharma Services, Cambridge Major Laboratories rebrand as Alcami

AAIPharma Services, Cambridge Major Laboratories rebrand as Alcami

April 5, 2016
CenterWatch Staff

AAIPharma Services (AAI) and Cambridge Major Laboratories (CML) are now Alcami, a new brand and identity as a contract development and manufacturing organization (CDMO) with expanded capabilities and capacity.

Originally joined together in late 2013, AAI and CML combined to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity.

"Alcami" represents the combination of the legacy company names in a contemporary coined name reflective of a transformation to become a worldclass solution provider to meet the growing pipeline of new products in development within the pharmaceutical and biotech industry. Improved quality and regulatory systems as well as operational performance are driving a culture of excellence across seven sites with nearly 1,000 employees in the U.S. and Europe.

Providing an integrated offering for both drug substance and drug product at every development stage beginning with solid state chemistry and formulation development, Alcami believes they have created a robust new outsourcing offering. Alcami also recently announced significant investments in additional capabilities and capacity for oral solid dose manufacturing, and parenteral fill-finish capabilities and capacity, including additional sterile lines and lyophilization capacity available now.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing